GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

QIAGEN ‘s QCI Interpret Software Enhances Clinical Reporting Speed for High-Throughput NGS Testing Labs

NextEdge Admin

14 Jun 2024

3 min 27 sec

QIAGEN has unveiled the latest iteration of its clinical decision support software, QCI Interpret, designed to cater to the evolving needs of high-throughput, next-generation sequencing (NGS) labs. This new version boasts significant performance and scalability enhancements tailored specifically for labs transitioning to larger test panels and handling higher test volumes.

The updated QCI Interpret leverages advanced artificial intelligence (AI) capabilities to introduce unprecedented workflow scalability and seamless test menu expansion. Among its new features are bulk variant assessment, flagging of co-occurring variants, enhanced test tracking, and additional multi-user functionality. These improvements aim to accelerate critical lab performance criteria such as turn-around-time, diagnostic yield, and quality results.

Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights, highlights the importance of this release amidst the genomic revolution, emphasizing the transition from single gene tests to comprehensive gene panels and even whole exome and genome sequencing. He notes that the latest QCI Interpret release enables labs to efficiently scale interpretation, identify relevant variants, and support clinical decisions faster.

Addressing the increasing demands on NGS labs to enhance productivity and efficiency while managing growing test volumes, QCI Interpret offers a unified system supporting the launch of additional panels without compromising turnaround times. The platform provides comprehensive content, streamlined case and workflow management, increased reporting flexibility, and simplified team coordination, ultimately reducing manual steps and saving considerable time for lab personnel.

Key features of the latest release include the Bulk Change Tool for faster variant assessment, early flagging of co-occurring variants with therapeutic significance, and enhanced tools for user group coordination and communication.

With over 850,000 clinical samples processed annually and trusted for analyzing over 4 million NGS patient test cases worldwide, QCI Interpret is recognized as the leading clinical decision support software globally. Its blend of expert curation and machine-powered AI ensures high-confidence variant interpretation and reporting, supporting critical decisions in oncology and hereditary diseases.

QCI Interpret's recent European IVDR certification as a Class C Medical Device further underscores its reliability and suitability for diagnostic use, solidifying its position as the go-to choice for labs and healthcare systems worldwide.